SavedAdd your journal

Journals / Solunum Hastalıkları / 2006 / Cilt: 17 - Sayı: 2

Pulmonary toxicity after low-dose amiodarone threapy (A case report)

Düşük doz amiodaron kullanımına bağlı pulmoner toksisite (Olgu sunumu)

Arzu ERTÜRK
Özcan KONUR
Meral GÜLHAN
Sema CANBAKAN
Nermin ÇAPAN
Pages
83–87
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Clinicians must remain alert to this possibility even with this low-dose therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amiodarone is an antiarrhythmic drug that can cause interstitial pneumonitis leading to pulmonary fibrosis.
📊
Key Findings & Data:A 65-year old man suffering from recurrent dyspnea was treated with a daily dose of 200 mg amiodarone.
💡
Conclusion & Impact:Clinicians must remain alert to this possibility even with this low-dose therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç toksisitesi · Amiodaron · Akciğer hastalıkları

Abstract

Amiodarone is an antiarrhythmic drug that can cause interstitial pneumonitis leading to pulmonary fibrosis. A 65-year old man suffering from recurrent dyspnea was treated with a daily dose of 200 mg amiodarone. Computed tomography revealed bilateral interstitial and alveolar opacifications with high-attenuating subpleural-parenchymal consolidations, suggesting amiodarone induced pneumonitis. Three months after cessation of amiodarone treatment, high resolution computerized tomography (HRCT) shows complete regression of pneumonitis. Amiodarone pneumonitis can be misinterpreted and mistreated in patients with further underlying diseases. The present case report demonstrates the diagnostic value of HRCT in the diagnosis of interstitial pneumonitis. Amiodarone-induced pulmonary toxicity can occur at a daily dose of 200 mg. Clinicians must remain alert to this possibility even with this low-dose therapy.

Özet

Amiodaron pulmoner fibrozise gidebilecek interstisyel pnömoniye neden olan antiaritmik bir ilaçtır. Altmışbeş yaşında dispne yakınması olan erkek hasta 200 mg/gün amiodaron kullanmaktaydı. Tomografi bulgularında amiodarona bağlı pulmoner toksisiteyi düşündüren bilateral interstisyel infiltrasyonlar ve subplevral ve parankimal konsolidasyonlar izlendi. Amiodaron tedavisi kesildikten üç ay sonra yüksek rezolüsyonlu bilgisayarlı tomografi (YRBT) bulgularında tam yanıt izlendi. Altta yatan hastalıklar nedeniyle amiodaron pnömonitisine yanlış tanı konup yanlış tedavi edilebilir. Bu olguda YRBT'nin interstisyel pnömoni tanısındaki değeri vurgulanmıştır. Amiodarona bağlı pulmoner toksisite 200 mg'lık düşük doz tedaviyle de ortaya çıkabilir. Klinisyen düşük doz amiodaron tedavisinde de bu komplikasyonlar yönünden uyanık olmalıdır.

🔖

Cite This Article

ERTÜRK, A., KONUR, Ö., GÜLHAN, M., CANBAKAN, S., ÇAPAN, N. (2006). Pulmonary toxicity after low-dose amiodarone threapy (A case report). Solunum Hastalıkları, Cilt: 17 - Sayı: 2, 83–87. https://ajindex.com/articles/318520

References (15)

  1. Machado RF, Dweik RA, Demeter SL, Ahmad M. Drug-induced pulmonary disease. In: Crapo JD, Clssroth J, Karlinsky J, Talmadge EK, eds. Pulmonary diseases. New York: Lippincott Williams and Wilkins, 2004;656-77
  2. Camus PH, Foucher P, Bonniaud PH, Ask K. Drug-induced infiltrative lung disease. Eur Respir J Suppl 2001;32:93-100
  3. Zitnik RJ, Matthay RA. Drug-induced pulmonary diseases. In: Schawartz Ml, King TE, eds. Interstitial lung disease. London: BC Decker Inc. Hamilton, 1998;423-49
  4. Camus P, Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Clin Chest Med 2004;25:65-75
  5. Kaushik S, Hussain A, Clarke P, Lazar HL Acute pulmonary toxicity after low-dose amiodarone therapy. Ann Thorac Surg 2001;72:1760-1
  6. Sunderji R, Kanji Z, Cin K. Pulmonary effects of low dose amiodarone: A review of the risks and recommendations for surveillance. Can J Cardiol 2000;16:1435-40
  7. Volperian VR, Havighurst TC, Miller S, et al. Advers effects of low dose amiodarone: A meta analysis. J Am Coll Cardiol 1997;30:791-8
  8. Ott MC, Khoor A, Leventhal JP, et al. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003;123:646-51
  9. Rodriguez-Carcia JL, Carcia-Nieto JC. Pulmonary mass and multiple lung nodules mimicking a lung neoplasm as amiodarone-induced pulmonary toxicity. Eur J Intern Med 2001;12:372-6
  10. Chuang CL, Chern MS, Chang SC. Amiodarone toxicity in a patient with simultaneous involvement of cornea, thyroid gland, and lung. Am J Med Sci 2000;320:64-8
  11. Burns KE, Piliotis E, Garcia BM, Ferguson KA. Amiodarone pulmonary, neuromuscular and ophthalmological toxicity. Can Respir J 2000;7:193-7
  12. Poll LW, May P, Koch JA, et al. HRCT findings of amiodarone pulmonary toxicity: Clinical and radiologic regression. J Cardiovasc Pharmacol Ther 2001;6:307-11
  13. Siniakowicz RM, Narula D, Suster B, Steinberg ]S. Diagnosis of amiodarone pulmonary toxicity with high-resolution computerized tomographic scan. Cardiovasc Electrophysiol 2001;12:431-6
  14. Dirlik A, Erine R, Ozcan Z, et al. Technetium-99m-DTPA aerosol scintigraphy in amiodarone induced pulmonary toxicity in comparison with Ga-67 scintigraphy. Ann Nud Med 2002;16:477-81
  15. Durmus-Altun G, Altun A, Aktas RG, et al. Use of iodine-123 metaiodobenzylguanidine scintigraphy for the detection of amiodarone induced pulmonary toxicity in a rabbit model: A comparative study with technetium- 99m diethyltriaminepenta acetic acid radioaerosol scintigraphy. Ann Nud Med 2005;19:217-24